tirzepatide death linked to lower risk for death, adverse CV and kidney outcomes vs. GLP-1s Unanticipated Adverse Events With Tirzepatide:
Description
Semaglutide timing matters for maximizing appetite suppression and minimizing nausea

Mounjaro is the latest GLP-1 to enter the increasingly crowded and complex GLP-1 market, joining Ozempic (indicated for diabetes, 2017) and Wegovy (indicated for weight loss, 2021) among others

Safe, personalized weight loss care across Louisiana and Mississippi.

@marxnchill asked about how her doctor wants to take her off GLP-1

A large clinical trial, co-led by researchers at the UNC School of Medicine, has shown that the popular weight-loss drug significantly reduces cardiovascular events in people with type 2 diabetes, pre-existing cardiovascular disease, and/or chronic kidney disease.